Abstract Library

#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education

Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Davies P,

Keywords: everolimus, patient education, side effects,

#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor

Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bouma G, De Vries E, Wymenga M, Walenkamp A,

Keywords: neuroendocrine, tumor, information, support, distress, quality, empowerment,

#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance

Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Leyden J, Sissons M, Goldstein G,

Keywords: neuroendocrine, advocacy, internet, facebook, twitter, social media,